SGSH
Showing 1 - 9 of 9
Mucopolysaccharidosis Type IIIA Trial in Worldwide (LYS-SAF302)
Active, not recruiting
- Mucopolysaccharidosis Type IIIA
-
Orange, California
- +7 more
Aug 30, 2021
Mucopolysaccharidosis Type IIIA Trial in Manchester (Autologous CD34+ cells transduced with a lentiviral vector containing the
Active, not recruiting
- Mucopolysaccharidosis Type IIIA
- Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene
-
Manchester, United KingdomManchester University NHS Foundation Trust
Jul 2, 2021
Study of Patients With MPS IIIA Treated With ABO-102
Enrolling by invitation
- Mucopolysaccharidosis III-A
- ABO-102
-
Columbus, Ohio
- +2 more
Nov 8, 2022
MPS IIIA, Sanfilippo Syndrome, Sanfilippo A Trial in Australia, Spain, United States (ABO-102)
Active, not recruiting
- MPS IIIA
- +3 more
- ABO-102
-
Columbus, Ohio
- +4 more
Nov 8, 2022
Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)
Active, not recruiting
- Mental Retardation
- Developmental Delay
-
Cairo, Egypt
- +4 more
May 12, 2021
Neuronal Ceroid Lipofuscinosis, Batten Disease, CLN1 Disease Trial in Hamburg (Natural History)
Recruiting
- Neuronal Ceroid Lipofuscinosis
- +14 more
- Natural History
-
Hamburg, GermanyUniversity Medical Center Hamburg-Eppendorf
Oct 22, 2021
Natural History Studies of Mucopolysaccharidosis III
Completed
- Mucopolysaccharidosis Type IIIA
- Mucopolysaccharidosis Type IIIB
- Lumbar puncture
- Magnetic Resonance Imaging (MRI) of the brain
-
Columbus, OhioNationwide Children's Hospital
Nov 12, 2015
Mucopolysaccharidosis Type III A, Sanfilippo Disease Type A Trial in Le Kremlin Bicêtre, Paris (SAF-301)
Completed
- Mucopolysaccharidosis Type III A
- Sanfilippo Disease Type A
- SAF-301
-
Le Kremlin Bicêtre, France
- +1 more
May 5, 2014